Related Experiment Video
Updated: May 7, 2026
08:51
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
Exploiting tumor epigenetics to improve oncolytic virotherapy.
Nicole E Forbes1, Hesham Abdelbary, Mathieu Lupien
1Center for Innovative Cancer Research, Ottawa Hospital Research Institute Ottawa, ON, Canada ; Faculty of Medicine, University of Ottawa Ottawa, ON, Canada.
Frontiers in Genetics
|September 25, 2013
Summary
Oncolytic viruses (OVs) are promising cancer therapies that replicate within tumors. Tumor epigenetics influences OV effectiveness and suggests new therapeutic strategies for improved cancer treatment.
Area of Science:
- Oncology
- Virology
- Genetics
Background:
- Oncolytic viruses (OVs) are a promising class of anticancer biologics that leverage tumor-specific defects for replication and tumor selectivity.
- Favorable tumor microenvironments, including increased metabolism and reduced immunity, support OV replication.
- Despite progress, challenges like tumor heterogeneity impact OV efficacy and anti-tumor immune responses.
Purpose of the Study:
- To review the role of the tumor epigenetic landscape in oncolytic virus (OV) infection.
- To explore how epigenetic modifications influence OV therapy effectiveness.
- To discuss therapeutic strategies that exploit tumor epigenetics to enhance OV-based cancer treatments.
Main Methods:
- Literature review focusing on the interplay between tumor epigenetics and oncolytic virotherapy.
- Analysis of current research on tumor heterogeneity and its impact on OV infection and immune response.
- Synthesis of evidence regarding epigenetic modifications and their influence on OV efficacy.
Main Results:
- Tumor epigenetics significantly impacts the tumor microenvironment's suitability for OV replication.
- Epigenetic variations contribute to tumor heterogeneity, affecting OV infection efficiency and the induction of anti-tumor immunity.
- Targeting epigenetic mechanisms presents a viable strategy to overcome OV resistance and improve therapeutic outcomes.
Conclusions:
- Tumor epigenetics is a critical factor influencing the success of oncolytic virus (OV) therapy.
- Understanding and manipulating the epigenetic landscape can enhance OV tumor selectivity and efficacy.
- Exploiting tumor epigenetics offers a promising avenue for developing more effective oncolytic virotherapy strategies.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:51Mechanisms of Retrovirus-induced Cancers
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...